Novartis Loses Glivec Patent Fight In India

Law360, New York (July 6, 2009, 12:00 AM EDT) -- A patent tribunal in India has rejected Novartis AG’s bid to secure a patent for its cancer drug Glivec, marking the latest chapter in the Swiss drugmaker's long-running battle with Indian patent law.

A Novartis representative confirmed Tuesday that India's Intellectual Property Appellate Board had denied a Novartis appeal of the Indian Patent Office's 2006 rejection of a patent for Glivec in beta crystal form.

In its ruling, the IPAB upheld objections to the patent under a legal provision unique to Indian patent law, the company...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.